A Correlative Imaging Study of in vivo and ex vivo Biodistribution of Solid Lipid Nanoparticles

References

• Wissing SA, Kayser O, Muller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Delivery Rev. 2004;56:1257–1272. doi:10.1016/j.addr.2003.12.002
   PubMed Web of Science ®Google Scholar
• Battaglia L, Gallarate M. Lipid nanoparticles: state of the art, new preparation methods and challenges in drug delivery. Expert Opin Drug Deliv. 2012;9:497–508. doi:10.1517/17425247.2012.67327822439808
   PubMed Web of Science ®Google Scholar
• Nyström AM, Fadeel B. Safety assessment of nanomaterials: implications for nanomedicine. J Controlled Rel. 2012;16:403–408. doi:10.1016/j.jconrel.2012.01.027
   Web of Science ®Google Scholar
• Masserini M. Nanoparticles for brain delivery. ISRN Biochem. 2013;18:238428.
   Google Scholar
• Muller RH, Gohla S, Mader K. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm. 2000;50:161–177.10840199
   PubMed Web of Science ®Google Scholar
• Mehnert W, Mader K. Solid lipid nanoparticles, production, characterization and applications. Adv Drug Delivery Rev. 2001;47:165–196.
   PubMed Web of Science ®Google Scholar
• Saupe A, Wissing SA, Lenk A, et al. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) – structural investigations on two different carrier systems. Bio-Med Mater Eng. 2005;15:393–402.
   PubMed Web of Science ®Google Scholar
• Uner M, Yener G. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int J Nanomedicine. 2007;2:289–300.18019829
   PubMed Web of Science ®Google Scholar
• Joshi MD, Müller RH. Lipid nanoparticles for parenteral delivery of actives. Eur J Pharm Biopharm. 2009;71:161–172.18824097
   PubMed Web of Science ®Google Scholar
• Pérez de la Ossa DH, Ligresti A, Gil-alegre ME, et al.. Poly-ε-caprolactone microspheres as a drug delivery system for cannabinoid administration: development, characterization and in vitro evaluation of their antitumoral efficacy. J Control Release. 2012;161(927–932).
   Google Scholar
• Shidhaye SS, Vaidya R, Sutar S, et al. Solid lipid nanoparticles and nanostructured lipid carriers–innovative generations of solid lipid carriers. Curr Drug Deliv. 2008;5:324–331. doi:10.2174/15672010878591508718855604
   PubMedGoogle Scholar
• Yoon G, Park JW, Yoon IS. Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs): recent advances in drug delivery. J Pharm Invest. 2013;43:353–362. doi:10.1007/s40005-013-0087-y
   Google Scholar
• Joshi M, Patravale V. Nanostructured lipid carrier (NLC) based gel of celecoxib. Int J Pharm. 2008;346:124–132. doi:10.1016/j.ijpharm.2007.05.06017651933
   PubMed Web of Science ®Google Scholar
• Lim SB, Banerjee A, Önyüksel H. Improvement of drug safety by the use of lipid-based nanocarriers. J Control Release. 2012;163:34–45. doi:10.1016/j.jconrel.2012.06.00222698939
   PubMed Web of Science ®Google Scholar
• Puri A, Loomis K, Smith B, et al. Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit Rev Ther Drug Carrier Syst. 2009;26:523–580. doi:10.1615/CritRevTherDrugCarrierSyst.v26.i6.1020402623
   PubMed Web of Science ®Google Scholar
• Esposito E, Cortesi R, Drechsler M, et al. Nanoformulations for dimethyl fumarate: physicochemical characterization and in vitro/in vivo behavior. Eur J Pharm Biopharm. 2017;115:285–296. doi:10.1016/j.ejpb.2017.04.01128412473
   PubMed Web of Science ®Google Scholar
• Doktorovova S, Souto EB, Silva AM. Nanotoxicology applied to solid lipid nanoparticles and nanostructured lipid carriers – a systematic review of in vitro data. Eur J Pharm Biopharm. 2014;87:1–18. doi:10.1016/j.ejpb.2014.02.00524530885
   PubMed Web of Science ®Google Scholar
• Lewinski N, Colvin V, Drezek R. Cytotoxicity of nanoparticles. Small. 2008;4(1):26–49. doi:10.1002/(ISSN)1613-682918165959
   PubMed Web of Science ®Google Scholar
• Li Q, Cai T, Huang Y, et al. A review of the structure, preparation, and application of NLCs, PNPs, and PLNs. Nanomaterials. 2017;7:122. doi:10.3390/nano7060122
   Web of Science ®Google Scholar
• Geszke-moritz M, Moritz M. Solid lipid nanoparticles as attractive drug vehicles: composition, properties and therapeutic strategies. Mater Sci Eng C Mater Biol Appl. 2016;68:982–994. doi:10.1016/j.msec.2016.05.11927524099
   PubMed Web of Science ®Google Scholar
• Poovaiah N, Davoudi Z, Peng H, et al. Treatment of neurodegenerative disorders through the blood-brain barrier using nanocarriers. Nanoscale. 2018;10(36):16962–16983. doi:10.1039/C8NR04073G30182106
   PubMed Web of Science ®Google Scholar
• Costa C, Moreira JN, Amaral MH, et al. Nose-to-brain delivery of lipid-based nanosystems for epileptic seizures and anxiety crisis. J Control Release. 2019;295:187–200. doi:10.1016/j.jconrel.2018.12.04930610952
   PubMed Web of Science ®Google Scholar
• Cacciatore I, Ciulla M, Fornasari E, et al. Solid lipid nanoparticles as a drug delivery system for the treatment of neurodegenerative diseases. Expert Opin Drug Deliv. 2016;13(8):1121–1131. doi:10.1080/17425247.2016.117823727073977
   PubMed Web of Science ®Google Scholar
• Gastaldi L, Battaglia L, Peira E, et al. Solid lipid nanoparticles as vehicles of drugs to the brain: current state of the art. Eur J Pharm Biopharm. 2014;87:433–444. doi:10.1016/j.ejpb.2014.05.00424833004
   PubMed Web of Science ®Google Scholar
• Sun W, Xie C, Wang H, et al. Specific role of polysorbate 80 coating on the targeting of nanoparticles to the brain. Biomaterials. 2004;25:3065–3071. doi:10.1016/j.biomaterials.2003.09.08714967540
   PubMed Web of Science ®Google Scholar
• Doktorovová S, Kovacˇevic´ AB, Garcia ML, et al. Preclinical safety of solid lipid nanoparticles and nanostructured lipid carriers: current evidence from in vitro and in vivo evaluation. Eur J Pharm Biopharm. 2016;108:235–252. doi:10.1016/j.ejpb.2016.08.00127519829
   PubMed Web of Science ®Google Scholar
• Del Pozo-Rodríguez A, Solinís MA, Rodríguez-gascón A. Applications of lipid nanoparticles in gene therapy. Eur J Pharm Biopharm. 2016;109:184–193. doi:10.1016/j.ejpb.2016.10.01627789356
   PubMed Web of Science ®Google Scholar
• Esposito E, Fantin M, Marti M, et al. Solid lipid nanoparticles as delivery systems for bromocriptine. Pharm Res. 2008;25:1521–1530. doi:10.1007/s11095-007-9514-y18172580
   PubMed Web of Science ®Google Scholar
• Pecora R. Dynamic light scattering measurement of nanometer particles in liquids. J Nanoparticle Res. 2000;2:123–131. doi:10.1023/A:1010067107182
   Web of Science ®Google Scholar
• Esposito E, De Vries HE, Van Der Pol SMA, et al. Production, physico-chemical characterization and biodistribution studies of lipid nanoparticles. J Nanomed Nanotechnol. 2015;6:1. doi:10.4172/2157-7439.1000256
   Google Scholar
• Marinozzi MR, Pandolfi L, Malatesta M, et al. Innovative approach to safely induce controlled lipolysis by superparamagnetic iron oxide nanoparticles-mediated hyperthermic treatment. Int J Biochem Cell Biol. 2017;93:62–73. doi:10.1016/j.biocel.2017.10.01329111382
   PubMed Web of Science ®Google Scholar
• Ramalingam P, Tag KY. Improved oral delivery of resveratrol from N-trimethyl chitosan-g-palmitic acid surface-modified solid lipid nanoparticles. Colloids Surf B Biointerfaces. 2016;139:52–61. doi:10.1016/j.colsurfb.2015.11.05026700233
   PubMed Web of Science ®Google Scholar
• Khosa A, Reddi S, Saha RN. Nanostructured lipid carriers for site-specific drug delivery. Biomed Pharmacother. 2018;103:598–613. doi:10.1016/j.biopha.2018.04.05529677547
   PubMed Web of Science ®Google Scholar
• Tapeinos C, Battaglini M, Ciofani G. Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases. J Control Release. 2017;28(264):306–332. doi:10.1016/j.jconrel.2017.08.033
   Google Scholar
• Cunha S, Amaral MH, Lobo JMS, et al. Lipid nanoparticles for nasal/intranasal drug delivery. Crit Rev Ther Drug Carrier Syst. 2017;34(3):257282. doi:10.1615/CritRevTherDrugCarrierSyst.2017018693
   Web of Science ®Google Scholar
• Jose S, Anju SS, Cinu TA, et al. In vivo pharmacokinetics and biodistribution of resveratrol-loaded solid lipid nanoparticles for brain delivery. Int J Pharm. 2014;474(1–2):6–13. doi:10.1016/j.ijpharm.2014.08.00325102112
   PubMed Web of Science ®Google Scholar
• Graverini G, Piazzini V, Landucci E, et al. Solid lipid nanoparticles for delivery of andrographolide across the blood-brain barrier: in vitro and in vivo evaluation. Colloids Surf B Biointerfaces. 2018;161:302–313. doi:10.1016/j.colsurfb.2017.10.06229096375
   PubMed Web of Science ®Google Scholar
• Shazly GA, Alshehri S, Ibrahim MA, et al. Development of domperidone solid lipid nanoparticles: in vitro and in vivo characterization. AAPS PharmSciTech. 2018;19(4):1712–1719. doi:10.1208/s12249-018-0987-229532427
   PubMed Web of Science ®Google Scholar
• Arantes VT, Faraco AAG, Ferreira FB, et al. Retinoic acid-loaded solid lipid nanoparticles surrounded by chitosan film support diabetic wound healing in in vivo study. Colloids Surf B Biointerfaces. 2019;188:110749. doi:10.1016/j.colsurfb.2019.11074931927466
   PubMed Web of Science ®Google Scholar
• El-gizawy SA, El-maghraby GM, Hedaya AA. Formulation of acyclovir-loaded solid lipid nanoparticles: 2. Brain targeting and pharmacokinetic study. Pharm Dev Technol. 2019;24(10):1299–1307. doi:10.1080/10837450.2019.166738631507245
   PubMed Web of Science ®Google Scholar
• Boschi F, Spinelli AE, D’ambrosio D, et al. Combined optical and single photon emission imaging: preliminary results. Phys Med Biol. 2009;54:L57–L62. doi:10.1088/0031-9155/54/23/L0119920307
   PubMed Web of Science ®Google Scholar
• Zelmer A, Ward TH. Noninvasive fluorescence imaging of small animals. J Microsc. 2013;252:8–15.23841905
   PubMed Web of Science ®Google Scholar
• Ghiani S, Capozza M, Cabella C, et al. In vivo tumor targeting and biodistribution evaluation of paramagnetic solid lipid nanoparticles for magnetic resonance imaging. Nanomedicine. 2017;13(2):693–700.27720928
   PubMed Web of Science ®Google Scholar
• Engin A. Non-alcoholic fatty liver disease. Adv Exp Med Biol. 2017;960:443–467.28585211
   PubMed Web of Science ®Google Scholar
• Brar G, Tsukamoto H. Alcoholic and non-alcoholic steatohepatitis: global perspective and emerging science. J Gastroenterol. 2019;54(3):218–225.30643981
   PubMed Web of Science ®Google Scholar
• Hojland Ipsen D, Lykkesfeldt J, Tveden‑nyborg P. Molecular mechanisms of hepatic lipid accumulation in non‑alcoholic fatty liver disease. Cell Mol Life Sci. 2018;75(18):3313–3327.29936596
   PubMed Web of Science ®Google Scholar
• Soto-gutierrez A, Gough A, Vernetti LA, et al. Preclinical and clinical investigations of metabolic zonation in liver diseases: the potential of microphysiology systems. Exp Biol Med (Maywood). 2017;242(16):1605–1616.28467181
   PubMed Web of Science ®Google Scholar
• Saxena R, Theise ND, Crawford JM. Microanatomy of human liver-exploring the hidden interfaces. Hepatology. 1999;30(6):1339–1346.10573509
   PubMed Web of Science ®Google Scholar
• Krishna M. Microscopic anatomy of the liver. Clin Liver Dis (Hoboken). 2013;2(Suppl 1):S4–S7.30992875
   PubMedGoogle Scholar
• Costanzo M, Carton F, Marengo A, et al. Fluorescence and electron microscopy to visualize the intracellular fate of nanoparticles for drug delivery. Eur J Histochem. 2016;60(2):2640.27349319
   PubMed Web of Science ®Google Scholar
• Verma A, Stellacci F. Effect of surface properties on nanoparticle-cell interactions. Small. 2010;6(1):12–21.19844908
   PubMed Web of Science ®Google Scholar
• Lanza R, Langer R, Vacanti JP. Principles of Tissue Engineering. 4th ed. New York: Academic Press; 2011.
   Google Scholar